Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236,234,693
-
Total 13F shares
-
40,805,612
-
Share change
-
-2,615,891
-
Total reported value
-
$360,286,694
-
Put/Call ratio
-
7.9%
-
Price per share
-
$8.83
-
Number of holders
-
126
-
Value change
-
-$30,324,254
-
Number of buys
-
58
-
Number of sells
-
68
Institutional Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2018
As of 30 Sep 2018,
Akebia Therapeutics, Inc. - Common Stock (AKBA) was held by
126 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,805,612 shares.
The largest 10 holders included
BlackRock Inc., Nantahala Capital Management, LLC, Novo Holdings A/S, Vanguard Group Inc, PERCEPTIVE ADVISORS LLC, STATE STREET CORP, MORGAN STANLEY, RENAISSANCE TECHNOLOGIES LLC, ABRAMS CAPITAL MANAGEMENT, L.P., and Clearbridge Investments, LLC.
This page lists
126
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.